On the antibiotic activity of oxazolomycin

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 4081-4086

  Bagwell, Claire L ^a   Moloney, Mark G ^a   Thompson, Amber L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibiotic; Bioactivity; Conformation; Oxazolomycin

Indexed keywords

ANTIBIOTIC AGENT; OXAZOLOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

AMINES; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HYDROGEN BONDING; HYDROPHOBICITY; LACTONES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OXAZOLES; SPIRO COMPOUNDS;

EID: 47149105034     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.105     Document Type: Article

References (44)

1. Moloney M.G., Trippier P.C., Yaqoob M., and Wang Z. Curr. Drug Discov. Technol. 1 (2004) 181
2. Mori T., Takahashi K., Kashiwabara M., Uemura D., Katayama C., Iwadare S., Shizuri Y., Mitomo R., Nakano F., and Matsuzaki A. Tetrahedron Lett. 26 (1985) 1073
3. Manam R.R., Teisan S., White D.J., Nicholson B., Grodberg J., Neuteboom S.T.C., Lam K.S., Mosca D.A., Lloyd G.K., and Potts B.C.M. J. Nat. Prod. 68 (2005) 240
4. Dorrestein P.C., Van Lanen S.G., Li W.L., Zhao C.H., Deng Z.X., Shen B., and Kelleher N.L. J. Am. Chem. Soc. 128 (2006) 10386
5. Zhao C.H., Ju J.H., Christenson S.D., Smith W.C., Song D.F., Zhou X.F., Shen B., and Deng Z.X. J. Bacteriol. 188 (2006) 4142
6. Onyango E.O., Tsurumoto J., Imai N., Takahashi K., Ishihara J., and Hatakeyama S. Angew. Chem., Int. Ed. 46 (2007) 6703
7. Kende A.S., Kawamura K., and DeVita R.J. J. Am. Chem. Soc. 112 (1990) 4070
8. Bennett N.J., Prodger J.C., and Pattenden G. Tetrahedron 63 (2007) 6216
9. Donohoe T.J., Chiu J.Y.K., and Thomas R.E. Org. Lett. 9 (2007) 421
10. Mohapatra D.K., Mondal D., Gonnade R.G., Chorghade M.S., and Gurjar M.K. Tetrahedron Lett. 47 (2006) 6031
11. Papillon J.P.N., and Taylor R.J.K. Org. Lett. 2 (2000) 1987
12. Andrews M.D., Brewster A.G., Crapnell K.M., Ibbett A.J., Jones T., Moloney M.G., Prout K., and Watkin D. J. Chem. Soc., Perkin Trans. 1 (1998) 223
13. Andrews M.D., Brewster A.G., and Moloney M.G. Synlett (1996) 612
14. Wang Z., and Moloney M.G. Tetrahedron Lett. 43 (2002) 9629
15. Marino J.P., and Nguyen H.N. Tetrahedron Lett. 44 (2003) 7395
16. Bulger P.G., Moloney M.G., and Trippier P.C. Org. Biomol. Chem. 1 (2003) 3726
17. Bulger P.G., Moloney M.G., and Trippier P.C. Synlett (2002) 1871
18. Addie M.S., and Taylor R.J.K. J. Chem. Soc., Perkin Trans. 1 (2000) 527
19. Webb M.R., Donald C., and Taylor R.J.K. Tetrahedron Lett. 47 (2006) 549
20. Whiting A., and Henaff N. Tetrahedron 56 (2000) 5193
21. Whiting A., and Henaff N. Org. Lett. 1 (1999) 1137
22. Ojika M., Itou Y., and Sakagami Y. Biosci. Biotechnol. Biochem. 67 (2003) 1568
23. Grigorjev P.A., Schlegel R., and Grafe U. Pharmazie 47 (1992) 707
24. Tonew E., Tonew M., Grafe U., and Zopel P. Acta Virol. 36 (1992) 166
25. Tonioloa C., Crismaa M., Formaggioa F., Peggiona C., Epand R.F., and Epand R.M. Cell. Mol. Life Sci. 58 (2001) 1179
26. Beesley R.M., Ingold C.K., and Thorpe J.F. J. Chem. Soc., Trans. 107 (1915) 1080
27. The preferred lowest energy conformation was calculated in the case of 3 and 4 AM1 semi-empirical calculations, and in the case of oxazolomycin 1b by using the Hartree-Fock method (6-31G* basis set) after the initial starting conformation was obtained from a sequential conformational search using CAChe Version 4.4.1 software. Kong J., White C.A., Krylov A.I., Sherrill C.D., Adamson R.D., Furlani T.R., Lee M.S., Lee A.M., Gwaltney S.R., Adams T.R., Ochsenfeld C., Gilbert A.T.B., Kedziora G.S., Rassolov V.A., Maurice D.R., Nair N., Shao Y., Besley N.A., Maslen P.E., Dombroski J.P., Daschel H., Zhang W., Korambath P.P., Baker J., Byrd E.F.C., Van Voorhis T., Oumi M., Hirata S., Hsu C.-P., Ishikawa N., Florian J., Warshel A., Johnson B.G., Gill P.M.W., Head-Gordon M., and Pople J.A. J. Comput. Chem. 21 (2000) 1532
28. Wang B., Gangwar S., Pauletti G.M., Siahaan T.J., and Borchardt R.T. J. Org. Chem. 62 (1997) 1363-1367
29. Miyoshi H., Tokutake N., Imaeda Y., Akagi T., and Iwamura H. Biochim. Biophys. Acta 1229 (1995) 149-154
30. Gaussier H., Lavoie M., and Subiradea M. Int. J. Biol. Macromol. 32 (2003) 1-9
31. Wedler C., Kunath A., and Schick H. J. Org. Chem. 60 (1995) 758
32. 2 requires 312.1934.
33. 41 Intensities were corrected for absorption effects by the multi-scan method, based on multiple scans of identical and Laue equivalent reflections. All non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were initially positioned geometrically and optimised using restraints, then refined using a riding model. Crystal data and structure refinement parameters are included in Table 3. Crystallographic data (excluding structure factors) for the structures in this letter have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 687802 and 687803. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223 336033 or e-mail: deposit@ccdc.cam.ac.uk.
34. 42-44 Microbiological assays were performed by the hole-plate method with the test organism Staphylococcus aureus N.C.T.C. 6571 or E. coli X580. Solutions (100 μl) of the compounds to be tested (4 mg/ml) were loaded into wells in bioassay plates, and incubated overnight at 37 °C. The diameters of the resultant inhibition zones were measured, and relative potency estimated by reference to standards prepared with Cephalosporin C. Minimum inhibitory concentrations were estimated by serial dilution until no inhibition zones were obtained after bioassay.
35. Otani T., Yoshida K.-I., Kubota H., Kawai S., Ito S., Hori H., Ishiyama T., and Oki T. J. Antibiot. 53 (2000) 1397
36. Kanzaki H., Wada K., Nitoda T., and Kawazu K. Biosci. Biotechnol. Biochem. 62 (1998) 438
37. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 46 (2001) 3
38. Quinn R.J., Carroll A.R., Pham N.B., Baron P., Palframan M.E., Suraweera L., Pierens G.K., and Muresan S. J. Nat. Prod. 71 (2008) 464
39. Cosier J., and Glazer A.M. J. Appl. Cryst. 19 (1986) 105
40. Otwinowski Z., and Minor W. Methods Enzymol. 276 (1997) 307
41. Betteridge P.W., Carruthers J.R., Cooper R.I., Prout K., and Watkin D.J. J. Appl. Cryst. 36 (2003) 1487
42. Smith B., Warren S.C., Newton G.G.F., and Abraham E.P. Biochem. J. 103 (1967) 877
43. Baldwin J.E., Coates J.B., Halpern J., Moloney M.G., and Pratt A.J. Biochem. J. 261 (1989) 197
44. Baldwin J.E., Pratt A.J., and Moloney M.G. Tetrahedron 43 (1987) 2565